Filing Overview
Nanobiotix S.A. filed a Form 6-K as a foreign private issuer on January 5, 2022. The filing identifies the company’s principal executive office in Paris, France, and confirms that it files annual reports on Form 20-F.
Business Context and Reporting Period
The filing is an exhibit submission rather than a financial-results filing. It references Exhibit 99.1, a press release dated January 5, 2022, but the press release text is not included in the provided filing content.
Financial Metrics
The filing text does not provide clear values for revenue, profit or loss, cash flow, margins, debt, liquidity, operating expenses, or other financial metrics.
Material Changes, Outlook, and Risks
The provided filing text does not describe material changes versus a prior period, guidance, outlook, management commentary, risks, contingencies, or unusual items. These matters may be addressed in Exhibit 99.1, which is referenced but not reproduced.
Investor Verification Items
- Obtain and review Exhibit 99.1, the January 5, 2022 press release.
- Verify whether the press release contains financial, clinical, regulatory, financing, or business updates not included in the filing text provided.
- Review Nanobiotix’s applicable Form 20-F and subsequent filings for financial condition, liquidity, debt, and risk disclosures.